Astellas discontinue darexaban development citing intensified competition

The oral anticoagulant market is one of the few primary care markets expected to grow significantly in the next few years, with a number of the new oral thrombin inhibitors and factor Xa inhibitors set to generate peak sales well in excess of $1billion.  … Continue reading

Pfizer’s tofacitinib appears to be as effective as Humira in Rheumatoid Arthritis (RA)

Pfizer provided details of tofacitinib data to be presented at the American College of Rheumatology (ACR) 2011 congress on 8 September.  The congress will be held on 5-9 November in Chicago. Tofacitinib is a novel, oral Janus kinase (JAK) inhibitor under … Continue reading